Print Friendly, PDF & Email

NCT/Study#

NCT02332850 /

139511-MMRC

A Phase Ib Study Of SAR650984 (Anti-CD38 Mab) In Combination With Carfilzomib For The Treatment Of Relapsed Or Refractory Multiple Myeloma

DISEASE GROUP:
Multiple Myeloma
current phase:
Phase I
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: